TY - JOUR
T1 - SARS-CoV-2 infection among patients with haematological disorders
T2 - Severity and one-month outcome in 66 Danish patients in a nationwide cohort study
AU - Glenthøj, Andreas
AU - Jakobsen, Lasse H
AU - Sengeløv, Henrik
AU - Ahmad, Syed A
AU - Qvist, Kristian
AU - Rewes, Annika
AU - Poulsen, Christian B
AU - Overgaard, Ulrik M
AU - Mølle, Ingolf
AU - Severinsen, Marianne T
AU - Strandholdt, Casper N
AU - Maibom, Jack
AU - Kodahl, Annette R
AU - Ryg, Jesper
AU - Ravn, Pernille
AU - Johansen, Isik S
AU - Helsø, Søren N
AU - Jensen-Fangel, Søren
AU - Kisielewicz, Jacek
AU - Wiese, Lothar
AU - Helleberg, Marie
AU - Kirk, Ole
AU - Clausen, Michael R
AU - Frederiksen, Henrik
N1 - © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2021/1
Y1 - 2021/1
N2 - OBJECTIVES: Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, this is unknown.METHODS: We conducted a prospective, nationwide study including 66 patients in follow-up at Danish haematology departments with a malignant or non-malignant haematological disorder and with verified SARS-CoV-2 infection. Outcomes were intensive care unit (ICU) admission and one-month survival rate.RESULTS: Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS-CoV-2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS-CoV-2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients.CONCLUSION: Haematological patients with SARS-CoV-2 infection has a severe clinical course.
AB - OBJECTIVES: Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, this is unknown.METHODS: We conducted a prospective, nationwide study including 66 patients in follow-up at Danish haematology departments with a malignant or non-malignant haematological disorder and with verified SARS-CoV-2 infection. Outcomes were intensive care unit (ICU) admission and one-month survival rate.RESULTS: Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS-CoV-2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS-CoV-2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients.CONCLUSION: Haematological patients with SARS-CoV-2 infection has a severe clinical course.
KW - immunology and infectious diseases
U2 - 10.1111/ejh.13519
DO - 10.1111/ejh.13519
M3 - Article
C2 - 32939853
SN - 0902-4441
VL - 106
SP - 72
EP - 81
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 1
ER -